Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Long acting beta agonists

¹Mater Adult Hospital.

Australian Family Physician

|January 27, 1999

Summary

This summary is machine-generated.

Long-acting beta agonists (LABAs) offer 12-hour asthma symptom control, especially at night. When combined with adequate inhaled corticosteroids (ICS), LABAs act as steroid-sparing agents without increasing exacerbations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.

HIV research & clinical practice·2020

Same author

Legionella longbeachae pneumonia as a complication of alemtuzumab therapy.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2017

Same author

Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016

Same author

Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.

Internal medicine journal·2016

Same author

Standard versus patient-centred asthma education in the emergency department: a randomised study.

The European respiratory journal·2008

Same author

Daily versus weekly azithromycin in cystic fibrosis patients.

The European respiratory journal·2007

Area of Science:

Pulmonology
Pharmacology

Background:

Long-acting beta agonists (LABAs) provide sustained bronchodilation for asthma management.
Emerging evidence highlights LABAs' potential as 'steroid-sparing' agents, enabling reduced inhaled corticosteroid (ICS) dosages.

Purpose of the Study:

To evaluate the efficacy and safety of LABA use in conjunction with adequate ICS for asthma control.
To assess the impact of LABA/ICS combination therapy on asthma exacerbations.

Main Methods:

Review of existing evidence on LABA and ICS combination therapy for asthma.
Analysis of studies examining asthma exacerbation rates in patients using adequate ICS doses with LABAs.

Main Results:

LABAs, such as salmeterol and eformoterol, offer 12-hour symptom control, improving nocturnal asthma.

Related Experiment Videos

When sufficient ICS doses (e.g., 800mcg beclomethasone/budesonide or 400mcg fluticasone) are used with LABAs, no increased risk of asthma exacerbation was observed.

Conclusions:

LABA/ICS combination therapy is effective for long-term asthma control.
The primary barrier to the broader clinical application of LABAs is their cost.